Indian Thought Latest News & Views
Pune. Children who have been deprived of the vaccine so far in the war against the corona virus, can soon get good news. The Phase 2/3 trial of the Covovax vaccine has started at Bharati Vidyapeeth Medical College, Pune on Wednesday. At present, this test is being done on children aged 7 to 11 years. Here, in Delhi also, the recruitment of volunteers has started for the Phase II trial of Kovovax at Hamdard Institute of Medical Sciences and Research
Sanjay Lalwani, Medical Director of the hospital said, “Bharti Vidyapeeth Medical College Hospital in Pune has started the 2/3 phase trial of Kovovax in children between 7 and 11 years of age on Wednesday. 9 children have been recruited for the trial. 9 centers have been identified in the country for testing this phase of the vaccine. Bharati Vidyapeeth Medical College Hospital is also included in this.
Dr Lalwani said that the parents of the children who wanted to join the trial were discussed earlier. He said, “Children seeking admission were given advice in the local language and the audio visual consulting process was recorded. Once the parents give consent, the volunteer undergoes an RT-PCR test and antibody test. However, this does not prevent him from being a part of the trial.
The process of vaccine trials against Kovid on children has started in India and the age of joining is 2 to 17 years. During the trial that started in Pune, the children will be given two doses at an interval of 21 days. The Indian version of the Novovax vaccine brought to India by the Serum Institute of India is Kovovax.
According to Bhasha, the recruitment of volunteers for the Phase II of the three clinical trials of the anti-Covid-19 vaccine Kovovax among children aged two to 17 years at the Hamdard Institute of Medical Sciences and Research began on Sunday. According to official sources, the test will be conducted at 10 locations and it will involve 920 children including 460-460 children in the age group of 12-17 and 2-11.
India’s drug regulator in July submitted recommendations to the Subject Expert Committee (CEC) on COVID-19 to Serum Institute of India (SII) for Phase II trial of Kovovax on children aged two to 17 years with certain conditions. was allowed on the basis of
